CY1119819T1 - Παραθυρεοειδης ορμονη (ρτη) για χρηση στην θεραπεια ισχαιμιας - Google Patents
Παραθυρεοειδης ορμονη (ρτη) για χρηση στην θεραπεια ισχαιμιαςInfo
- Publication number
- CY1119819T1 CY1119819T1 CY20171101335T CY171101335T CY1119819T1 CY 1119819 T1 CY1119819 T1 CY 1119819T1 CY 20171101335 T CY20171101335 T CY 20171101335T CY 171101335 T CY171101335 T CY 171101335T CY 1119819 T1 CY1119819 T1 CY 1119819T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pth
- parathyroid hormone
- pthrp
- present
- ischemia
- Prior art date
Links
- 108090000445 Parathyroid hormone Proteins 0.000 title abstract 10
- 102000003982 Parathyroid hormone Human genes 0.000 title abstract 8
- 239000000199 parathyroid hormone Substances 0.000 title abstract 8
- 229960001319 parathyroid hormone Drugs 0.000 title abstract 6
- 230000000302 ischemic effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000028867 ischemia Diseases 0.000 abstract 3
- ZOWOHMFPXMYFKJ-WBTWNKCNSA-N (4S)-4-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]-5-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(1S)-1-carboxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)[C@@H](C)CC)C1=CN=CN1 ZOWOHMFPXMYFKJ-WBTWNKCNSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108010054971 parathyroid hormone-related protein (1-34) Proteins 0.000 abstract 2
- 210000000130 stem cell Anatomy 0.000 abstract 2
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 abstract 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση αφορά σε χρήσεις και μεθόδους παραθυρεοειδούς ορμόνης (ΡΤΗ), κατά προτίμηση ΡΤΗ (1-34) ή/και σχετικού με παραθυρεοειδή ορμόνη πεπτιδίου (PTHrP), κατά προτίμηση PTHrP (1-34), για πρόσληψη βλαστοκυττάρων επί ιστού που υποφέρει από ισχαιμία, όπου τα εν λόγω βλαστοκύτταρα κατά προτίμηση είναι ικανά αποκατάστασης ή/και αναγέννησης του εν λόγω ιστού που υποφέρει από ισχαιμία. Συνεπώς, οι χρήσεις και οι μέθοδοι της παρούσας εφεύρεσης κατά προτίμηση είναι κατάλληλες για την πρόληψη ή/και θεραπεία ισχαιμίας. Επιπλέον, η παρούσα εφεύρεση αφορά σε μία σύνθεση που περιλαμβάνει παραθυρεοειδή ορμόνη (ΡΤΗ), κατά προτίμηση ΡΤΗ (1-34) ή/και σχετικό με παραθυρεοειδή ορμόνη πεπτίδιο (PTHrP), κατά προτίμηση PTHrP (1-34) ή/και G-CSF ή/και θραύσμα G-CSF για χρήση ως φαρμακευτική σύνθεση. Σε μια ιδιαίτερη άποψη, ένας ανταγωνιστής DPP IV εφαρμόζεται στις χρήσεις, μεθόδους ή/και συνθέσεις της παρούσας εφεύρεσης.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79294306P | 2006-04-19 | 2006-04-19 | |
| PCT/EP2007/003272 WO2007118680A2 (en) | 2006-04-19 | 2007-04-12 | Remedies for ischemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119819T1 true CY1119819T1 (el) | 2018-06-27 |
Family
ID=38609853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101335T CY1119819T1 (el) | 2006-04-19 | 2017-12-20 | Παραθυρεοειδης ορμονη (ρτη) για χρηση στην θεραπεια ισχαιμιας |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8207116B2 (el) |
| EP (1) | EP2007416B1 (el) |
| CY (1) | CY1119819T1 (el) |
| DK (1) | DK2007416T3 (el) |
| ES (1) | ES2654251T3 (el) |
| HU (1) | HUE035446T2 (el) |
| LT (1) | LT2007416T (el) |
| PL (1) | PL2007416T3 (el) |
| PT (1) | PT2007416T (el) |
| SI (1) | SI2007416T1 (el) |
| WO (1) | WO2007118680A2 (el) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2138572A1 (en) * | 2008-06-26 | 2009-12-30 | t2cure GmbH | Mesoangioblast-like cell as well as methods and uses relating thereto |
| WO2010045229A2 (en) | 2008-10-13 | 2010-04-22 | University Of Rochester | Protecting and repairing cartilage and musculoskeletal soft tissues |
| GB201619861D0 (en) * | 2016-11-24 | 2017-01-11 | Narodden Salomon | Treatments for heart failure and cardiac ischaemic reperfusion injury |
| US20210380937A1 (en) * | 2017-04-04 | 2021-12-09 | The Board Of Trustees Of The Leland Stanford Junior University | Preparation , expansion, and uses of adult pluripotent stem cells |
| JP7329265B2 (ja) | 2018-09-21 | 2023-08-18 | アプステム セラピューティクス、インコーポレイテッド | ヒト多能性成人幹細胞 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030181373A1 (en) * | 2000-08-11 | 2003-09-25 | Toshio Ohhashi | Vascular relaxation agents |
| US20040161412A1 (en) | 2002-08-22 | 2004-08-19 | The Cleveland Clinic Foundation | Cell-based VEGF delivery |
| US7384786B2 (en) * | 2003-07-16 | 2008-06-10 | Scimed Life Systems, Inc. | Aligned scaffolds for improved myocardial regeneration |
| EP1527785A1 (en) | 2003-10-27 | 2005-05-04 | Ludwig-Maximilians-Universität München | Use of G-CSF for treating ischemia |
| KR20170005163A (ko) * | 2003-11-17 | 2017-01-11 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
| US20070021336A1 (en) * | 2004-12-24 | 2007-01-25 | Christen Anderson | Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis |
| US7393827B2 (en) * | 2004-12-30 | 2008-07-01 | Diakine Therapeutics, Inc. | Pharmaceutical compositions and methods for restoring β-cell mass and function |
-
2007
- 2007-04-12 PL PL07724213T patent/PL2007416T3/pl unknown
- 2007-04-12 EP EP07724213.9A patent/EP2007416B1/en active Active
- 2007-04-12 ES ES07724213.9T patent/ES2654251T3/es active Active
- 2007-04-12 WO PCT/EP2007/003272 patent/WO2007118680A2/en active Application Filing
- 2007-04-12 DK DK07724213.9T patent/DK2007416T3/en active
- 2007-04-12 PT PT77242139T patent/PT2007416T/pt unknown
- 2007-04-12 HU HUE07724213A patent/HUE035446T2/en unknown
- 2007-04-12 LT LTEP07724213.9T patent/LT2007416T/lt unknown
- 2007-04-12 SI SI200731997T patent/SI2007416T1/en unknown
- 2007-04-12 US US12/296,584 patent/US8207116B2/en not_active Expired - Fee Related
-
2017
- 2017-12-20 CY CY20171101335T patent/CY1119819T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007118680A2 (en) | 2007-10-25 |
| ES2654251T3 (es) | 2018-02-12 |
| SI2007416T1 (en) | 2018-02-28 |
| PT2007416T (pt) | 2018-01-03 |
| US8207116B2 (en) | 2012-06-26 |
| US20090286730A1 (en) | 2009-11-19 |
| DK2007416T3 (en) | 2017-12-11 |
| PL2007416T3 (pl) | 2018-05-30 |
| HUE035446T2 (en) | 2018-05-02 |
| EP2007416A2 (en) | 2008-12-31 |
| WO2007118680A3 (en) | 2008-02-14 |
| LT2007416T (lt) | 2018-02-12 |
| EP2007416B1 (en) | 2017-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119819T1 (el) | Παραθυρεοειδης ορμονη (ρτη) για χρηση στην θεραπεια ισχαιμιας | |
| CY1122134T1 (el) | Συνθεση για χρηση στη θεραπευτικη αντιμετωπιση της γαστρεντερικης δυσκινησιας | |
| CY1120022T1 (el) | Θεραπεια παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας | |
| CY1118731T1 (el) | Φαρμακευτικες συνθεσεις αλβιγλουτιδης | |
| CY1117584T1 (el) | Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1 | |
| MX341883B (es) | Composicion farmaceutica para el tratamiento y prevencion de canceres. | |
| EA200900098A1 (ru) | Пептидные соединения для лечения расстройств, связанных с повышенной возбудимостью, и болезней, связанных с дисфункцией ионных каналов | |
| BR112015009037A2 (pt) | composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1 | |
| CR20110221A (es) | Terapia de combinación con péptidos epoxicetonas peptídicas | |
| HK1112367A1 (en) | Survivin peptide vaccine | |
| EA201391000A1 (ru) | Индольные соединения или их аналоги, полезные для лечения возрастной макулярной дегенерации (amd) | |
| EA201290322A1 (ru) | Лечение желудочно-кишечных расстройств | |
| BR0308429A (pt) | Aroilpiridinonas monocìclicas como agentes antiinflamatórios | |
| CY1118947T1 (el) | Ασυμμετρες ουριες και ιατρικες χρησεις αυτων | |
| BRPI0720551A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| EA201170441A1 (ru) | Терапевтические противовирусные пептиды | |
| EA201390428A1 (ru) | Композиции и способы лечения легочной гипертензии | |
| NO20080745L (no) | Nye peptider for anvendelse i behandling av fedme | |
| EA201170753A1 (ru) | Налмефена гидрохлорид дигидрат | |
| CY1117504T1 (el) | Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, και cx3cr1 | |
| CL2011000571A1 (es) | Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma. | |
| HK1126856A1 (en) | Methods for identifying polypeptide targets | |
| CY1120852T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας | |
| CL2007000595A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras. | |
| EA201891416A1 (ru) | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА |